Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Expects Q1 Organic Revenue Growth of 10 Percent

NEW YORK (GenomeWeb News) – Bruker said after the close of the market last night that it expects to report first-quarter revenues of around $400 million with organic revenue growth of around 10 percent year over year.

The firm pre-announced the revenue figure a day after competitor Waters surprised the market by reporting a 2 percent decline for its Q1 revenues year over year, citing weaker sales in certain developing markets as well as reluctance by several larger pharmaceutical firms to release their capital budgets. It missed Wall Street estimates on the top and bottom line.

The $400 revenue figure is above Bruker's guidance of $380 million to $390 million and above Wall Street's consensus estimate of $386.9 million.

Bruker will report its financial results and hold a conference call on May 1.

In early Wednesday trade on the Nasdaq, shares of Bruker were up 6 percent at $14.66. The shares had fallen around 4 percent on Tuesday.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.